DK1011648T4 - Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer - Google Patents

Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer

Info

Publication number
DK1011648T4
DK1011648T4 DK98942057T DK98942057T DK1011648T4 DK 1011648 T4 DK1011648 T4 DK 1011648T4 DK 98942057 T DK98942057 T DK 98942057T DK 98942057 T DK98942057 T DK 98942057T DK 1011648 T4 DK1011648 T4 DK 1011648T4
Authority
DK
Denmark
Prior art keywords
tyrosine kinase
kinase inhibitor
prostate cancer
combination
chemical castration
Prior art date
Application number
DK98942057T
Other languages
Danish (da)
English (en)
Other versions
DK1011648T3 (da
Inventor
Jeffry L Vaught
Craig A Dionne
John Isaacs
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1011648(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of DK1011648T3 publication Critical patent/DK1011648T3/da
Application granted granted Critical
Publication of DK1011648T4 publication Critical patent/DK1011648T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
DK98942057T 1997-08-15 1998-08-13 Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer DK1011648T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15
PCT/US1998/016849 WO1999008668A2 (fr) 1997-08-15 1998-08-13 Inhibiteur de tyrosine kinase combine a une castration chimique pour traiter un cancer de la prostate

Publications (2)

Publication Number Publication Date
DK1011648T3 DK1011648T3 (da) 2001-12-27
DK1011648T4 true DK1011648T4 (da) 2005-10-24

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98942057T DK1011648T4 (da) 1997-08-15 1998-08-13 Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer

Country Status (22)

Country Link
US (1) US5985877A (fr)
EP (1) EP1011648B2 (fr)
JP (1) JP2001515032A (fr)
KR (1) KR100612161B1 (fr)
CN (1) CN1147317C (fr)
AT (1) ATE208210T1 (fr)
AU (1) AU737092B2 (fr)
BR (1) BR9812122A (fr)
CA (1) CA2299471C (fr)
CZ (1) CZ297198B6 (fr)
DE (1) DE69802422T3 (fr)
DK (1) DK1011648T4 (fr)
EA (1) EA002525B1 (fr)
ES (1) ES2163293T5 (fr)
HU (1) HUP0003194A3 (fr)
NO (1) NO325526B1 (fr)
NZ (2) NZ517497A (fr)
PL (1) PL193375B1 (fr)
PT (1) PT1011648E (fr)
TR (1) TR200000415T2 (fr)
UA (1) UA61970C2 (fr)
WO (1) WO1999008668A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103761A3 (en) * 1998-10-08 2002-11-28 Takeda Chemical Industries Ltd Compositions for retarding change of hormone-dependent cancer into hormone-independent cancer and their use
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
AU2002315306B2 (en) * 2001-05-08 2007-05-17 Merck Patent Gmbh Combination therapy using anti-EGFR antibodies and anti-hormonal agents
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
ES2388170T3 (es) * 2001-08-24 2012-10-09 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
WO2006047639A2 (fr) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
EP1869192B1 (fr) 2005-03-18 2016-01-20 MedImmune, LLC Rearrangement de l'infrastructure d'anticorps
US8916161B2 (en) 2005-06-14 2014-12-23 Sophiris Bio Inc. Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
KR101353706B1 (ko) * 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US20090130195A1 (en) 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
EP3763740A1 (fr) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2015053871A2 (fr) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. Acides nucléiques codant des anticorps humains contre sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
WO2016094837A2 (fr) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
JP6974178B2 (ja) 2015-05-29 2021-12-01 メモリアル スローン ケタリング キャンサー センター フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法
EP3383908A1 (fr) 2015-12-02 2018-10-10 Stsciences, Inc. Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3634500B1 (fr) 2017-05-25 2023-10-25 Memorial Sloan-Kettering Cancer Center Nanoparticules ultra-petites marquées avec du zirconium-89 et leurs procédés
WO2018222685A1 (fr) 2017-05-31 2018-12-06 Stcube & Co., Inc. Méthodes de traitement du cancer à l'aide d'anticorps et de molécules se liant de manière immunospécifique à btn1a1
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3635007A1 (fr) 2017-06-06 2020-04-15 STCube & Co., Inc. Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4923986A (en) † 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5461146A (en) † 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
EP0699204B1 (fr) * 1993-05-28 1998-04-15 Cephalon, Inc. Utilisation de derives de l'indolocarbozole pour traiter une affection de la prostate
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) † 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
CA2260999C (fr) † 1996-07-19 2006-07-11 Takeda Chemical Industries, Ltd. Composes heterocycliques, leur production et leur utilisation en tant qu'inhibiteurs de tyrosine kinase

Also Published As

Publication number Publication date
DE69802422D1 (de) 2001-12-13
HK1028565A1 (en) 2001-02-23
ES2163293T3 (es) 2002-01-16
KR20010022878A (ko) 2001-03-26
WO1999008668A2 (fr) 1999-02-25
HUP0003194A3 (en) 2003-03-28
BR9812122A (pt) 2000-07-18
JP2001515032A (ja) 2001-09-18
AU9019298A (en) 1999-03-08
CZ297198B6 (cs) 2006-09-13
EP1011648A2 (fr) 2000-06-28
PL338885A1 (en) 2000-11-20
DK1011648T3 (da) 2001-12-27
PL193375B1 (pl) 2007-02-28
ATE208210T1 (de) 2001-11-15
AU737092B2 (en) 2001-08-09
EP1011648B1 (fr) 2001-11-07
UA61970C2 (en) 2003-12-15
WO1999008668A3 (fr) 1999-04-15
NZ517497A (en) 2004-11-26
EP1011648B2 (fr) 2005-07-20
DE69802422T3 (de) 2005-12-29
NO325526B1 (no) 2008-06-02
US5985877A (en) 1999-11-16
CN1268061A (zh) 2000-09-27
DE69802422T2 (de) 2002-07-11
ES2163293T5 (es) 2006-01-16
CZ2000469A3 (cs) 2001-08-15
EA200000220A1 (ru) 2000-10-30
TR200000415T2 (tr) 2000-08-21
PT1011648E (pt) 2002-03-28
CN1147317C (zh) 2004-04-28
NO20000732L (no) 2000-03-28
KR100612161B1 (ko) 2006-08-14
NO20000732D0 (no) 2000-02-14
HUP0003194A2 (hu) 2001-07-30
NZ502646A (en) 2002-04-26
CA2299471A1 (fr) 1999-02-25
CA2299471C (fr) 2007-12-18
EA002525B1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
DK1011648T3 (da) Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer
DK1019060T3 (da) Androgensynteseinhibitorer
ATE399007T1 (de) Raf kinase hemmer
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY121548A (en) Compounds and methods for the treatment of cancer
DE69815313D1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
DE69333711D1 (de) Compactin zur behandlung von entzündungen
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
ATE361075T1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
IL129705A0 (en) Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
DK0891344T3 (da) Antagonister til alpha-1-adrenergisk receptor
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.
ITMI920850A0 (it) Benzofurano-imidazoli per uso come inibitori di aromatisie 17,20-liasinella rpofilassi e trattamento del cancro della mammella e nell'iper- plasia prostatica benigna